TD Cowen analyst Mathew Blackman downgraded Insulet (PODD) to Hold from Buy with a $294 price target as the analyst took over coverage of the stock. Insulet has momentum, as O5 is capturing patients, driving top-tier growth, the analyst tells investors in a research note. The company wins on form factor/pharmacy, but the world is not static and the advantages compared to peers will likely narrow, the analyst adds. The firm also noted that while there are still growth opportunities and a visible pipeline, it sees modest upside ahead.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Balanced Risk–Reward for Insulet: Strong Growth but Rising Competition Justifies Hold Rating and $294 Target
- Insulet Completes Key Omnipod 5 SmartAdjust 2.0 Study, Setting Up Next Growth Phase
- Netflix initiated, Palantir upgraded: Wall Street’s top analyst calls
- Barclays downgrades Insulet to Underweight on intensifying competition
- Insulet downgraded to Underweight from Equal Weight at Barclays